Weinan Dong

Weinan Dong

Auto-generated profile, based on publicly available information

Weinan Dong

Department of Family Medicine and Primary Care The University of Hong Kong Hong Kong China

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 October 2021 in Journal of Medical Internet Research
Verified
Journal Article
Open access
IZIvy Yan Zhao
Ivy Yan Zhao
YMYe Xuan Ma
Ye Xuan Ma
MYMan Wai Cecilia Yu
Man Wai Cecilia Yu
JLJia Liu
Jia Liu
WDWei Nan Dong
Wei Nan Dong
WWWilliam Chi Wai Wong
William Chi Wai Wong
Background: The COVID-19 pandemic has increased the importance of the deployment of digital detection surveillance systems to support early warning and monitoring of infectious diseases. These opportunities create a “double-edge sword,” as the ethical governance of such approaches often lags behind technological achievements. Objective: The aim was to investigate ethical issues identified from utilizing artificial intelligence–augmented surveillance or early warning systems to monitor and detect common or novel infectious disease outbreaks. Methods: In a number of databases, we searched relevant articles that addressed ethical issues of using artificial intelligence, digital surveillance systems, early warning systems, and/or big data analytics technology for detecting, monitoring, or tracing infectious diseases according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, and further identified and analyzed them with a theoretical framework. Results: This systematic review identified 29 articles presented in 6 major themes clustered under individual, organizational, and societal levels, including awareness of implementing digital surveillance, digital integrity, trust, privacy and confidentiality, civil rights, and governance. While these measures were understandable during a pandemic, the public had concerns about receiving inadequate information; unclear governance frameworks; and lack of privacy protection, data integrity, and autonomy when utilizing infectious disease digital surveillance. The barriers to engagement could widen existing health care disparities or digital divides by underrepresenting vulnerable and at-risk populations, and patients’ highly sensitive data, such as their movements and contacts, could be exposed to outside sources, impinging significantly upon basic human and civil rights. Conclusions: Our findings inform ethical considerations for service delivery models for medical practitioners and policymakers involved in the use of digital surveillance for infectious disease spread, and provide a basis for a global governance structure. Trial Registration: PROSPERO CRD42021259180; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=259180

15 July 2024 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
WDWeinan Dong
Weinan Dong
EWEric Yuk Fai Wan
Eric Yuk Fai Wan
DFDaniel Yee Tak Fong
Daniel Yee Tak Fong
KTKathryn Choon‐Beng Tan
Kathryn Choon‐Beng Tan
WTWendy Wing‐Sze Tsui
Wendy Wing‐Sze Tsui
CLCindy L.K. Lam
Cindy L.K. Lam
Aim: To develop 10‐year cardiovascular disease (CVD) risk prediction models in Chinese patients with type 2 diabetes mellitus (T2DM) managed in primary care using machine learning (ML) methods. Methods: In this 10‐year population‐based retrospective cohort study, 141 516 Chinese T2DM patients aged 18 years or above, without history of CVD or end‐stage renal disease and managed in public primary care clinics in 2008, were included and followed up until December 2017. Two‐thirds of the patients were randomly selected to develop sex‐specific CVD risk prediction models. The remaining one‐third of patients were used as the validation sample to evaluate the discrimination and calibration of the models. ML‐based methods were applied to missing data imputation, predictor selection, risk prediction modelling, model interpretation, and model evaluation. Cox regression was used to develop the statistical models in parallel for comparison. Results: During a median follow‐up of 9.75 years, 32 445 patients (22.9%) developed CVD. Age, T2DM duration, urine albumin‐to‐creatinine ratio (ACR), estimated glomerular filtration rate (eGFR), systolic blood pressure variability and glycated haemoglobin (HbA1c) variability were the most important predictors. ML models also identified nonlinear effects of several predictors, particularly the U‐shaped effects of eGFR and body mass index. The ML models showed a Harrell's C statistic of >0.80 and good calibration. The ML models performed significantly better than the Cox regression models in CVD risk prediction and achieved better risk stratification for individual patients. Conclusion: Using routinely available predictors and ML‐based algorithms, this study established 10‐year CVD risk prediction models for Chinese T2DM patients in primary care. The findings highlight the importance of renal function indicators, and variability in both blood pressure and HbA1c as CVD predictors, which deserve more clinical attention. The derived risk prediction tools have the potential to support clinical decision making and encourage patients towards self‐care, subject to further research confirming the models’ feasibility, acceptability and applicability at the point of care.

15 December 2020 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
PDF file
WDWeinan Dong
Weinan Dong
EWEric Yuk Fai Wan
Eric Yuk Fai Wan
DFDaniel Yee Tak Fong
Daniel Yee Tak Fong
RKRuby Lai Ping Kwok
Ruby Lai Ping Kwok
DCDavid Vai Kiong Chao
David Vai Kiong Chao
CLCindy Lo Kuen Lam
Cindy Lo Kuen Lam

10 February 2024 in Annals of Medicine
Verified
Journal Article
Open access
WDWeinan Dong
Weinan Dong
CRCecilia Clara Da Roza
Cecilia Clara Da Roza
DCDandan Cheng
Dandan Cheng
DZDahao Zhang
Dahao Zhang
YXYuling Xiang
Yuling Xiang
WWWilliam Chi Wai Wong
William Chi Wai Wong
The construction of a robust healthcare information system is fundamental to enhancing countries' capabilities in the surveillance and control of hepatitis B virus (HBV). Making use of China's rapidly expanding primary healthcare system, this innovative approach using big data and machine learning (ML) could help towards the World Health Organization's (WHO) HBV infection elimination goals of reaching 90% diagnosis and treatment rates by 2030. We aimed to develop and validate HBV detection models using routine clinical data to improve the detection of HBV and support the development of effective interventions to mitigate the impact of this disease in China. Relevant data records extracted from the Family Medicine Clinic of the University of Hong Kong-Shenzhen Hospital's Hospital Information System were structuralized using state-of-the-art Natural Language Processing techniques. Several ML models have been used to develop HBV risk assessment models. The performance of the ML model was then interpreted using the Shapley value (SHAP) and validated using cohort data randomly divided at a ratio of 2:1 using a five-fold cross-validation framework. The patterns of physical complaints of patients with and without HBV infection were identified by processing 158,988 clinic attendance records. After removing cases without any clinical parameters from the derivation sample (n = 105,992), 27,392 cases were analysed using six modelling methods. A simplified model for HBV using patients' physical complaints and parameters was developed with good discrimination (AUC = 0.78) and calibration (goodness of fit test p-value >0.05). Suspected case detection models of HBV, showing potential for clinical deployment, have been developed to improve HBV surveillance in primary care setting in China. (Word count: 264).

23 July 2021 in JMIR Preprints
Verified
Preprint
Open access
IZIvy Yan Zhao
Ivy Yan Zhao
YMYe Xuan Ma
Ye Xuan Ma
MYMan Wai Cecilia Yu
Man Wai Cecilia Yu
JLJia Liu
Jia Liu
WDWei Nan Dong
Wei Nan Dong
WWWilliam Chi Wai Wong
William Chi Wai Wong
BACKGROUND The COVID-19 pandemic has increased the importance of the deployment of digital detection surveillance systems to support early warning and monitoring of infectious diseases. These opportunities create a “double-edge sword,” as the ethical governance of such approaches often lags behind technological achievements. OBJECTIVE The aim was to investigate ethical issues identified from utilizing artificial intelligence–augmented surveillance or early warning systems to monitor and detect common or novel infectious disease outbreaks. METHODS In a number of databases, we searched relevant articles that addressed ethical issues of using artificial intelligence, digital surveillance systems, early warning systems, and/or big data analytics technology for detecting, monitoring, or tracing infectious diseases according to PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines, and further identified and analyzed them with a theoretical framework. RESULTS This systematic review identified 29 articles presented in 6 major themes clustered under individual, organizational, and societal levels, including awareness of implementing digital surveillance, digital integrity, trust, privacy and confidentiality, civil rights, and governance. While these measures were understandable during a pandemic, the public had concerns about receiving inadequate information; unclear governance frameworks; and lack of privacy protection, data integrity, and autonomy when utilizing infectious disease digital surveillance. The barriers to engagement could widen existing health care disparities or digital divides by underrepresenting vulnerable and at-risk populations, and patients’ highly sensitive data, such as their movements and contacts, could be exposed to outside sources, impinging significantly upon basic human and civil rights. CONCLUSIONS Our findings inform ethical considerations for service delivery models for medical practitioners and policymakers involved in the use of digital surveillance for infectious disease spread, and provide a basis for a global governance structure. CLINICALTRIAL PROSPERO CRD42021259180; https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=259180